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The new combination between the nucleoside analogue gemcitabine and the cholesterol-lowering drug fluvastatin was investigated in
vitro and in vivo on the human pancreatic tumour cell line MIAPaCa-2. The present study demonstrates that fluvastatin inhibits
proliferation, induces apoptosis in pancreatic cancer cells harbouring a p21ras mutation at codon 12 and synergistically potentiates the
cytotoxic effect of gemcitabine. The pharmacologic activities of fluvastatin are prevented by administration of mevalonic acid,
suggesting that the shown inhibition of geranyl-geranylation and farnesylation of cellular proteins, including p21rhoA and p21ras, plays
a major role in its anticancer effect. Fluvastatin treatment also indirectly inhibits the phosphorylation of p42ERK2/mitogen-activated
protein kinase, the cellular effector of ras and other signal transduction peptides. Moreover, fluvastatin administration significantly
increases the expression of the deoxycytidine kinase, the enzyme required for the activation of gemcitabine, and simultaneously
reduces the 50-nucleotidase, responsible for deactivation of gemcitabine, suggesting a possible additional role of these enzymes in the
enhanced cytotoxic activity of gemcitabine. Finally, a significant in vivo antitumour effect on MIAPaCa-2 xenografts was observed with
the simultaneous combination of fluvastatin and gemcitabine, resulting in an almost complete suppression and a marked delay in
relapse of tumour growth. In conclusion, the combination of fluvastatin and gemcitabine is an effective cytotoxic, proapoptotic
treatment in vitro and in vivo against MIAPaCa-2 cells by a mechanism of action mediated, at least in part, by the inhibition of p21ras
and rhoA prenylation. The obtained experimental findings might constitute the basis for a novel translational research in humans.
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Pancreas cancer represents a model of carcinogenesis in which the
mutational activation of the k-ras oncogene is present in up to 90%
of cases, and is supposed to play a relevant role in tumour
progression and aggressive behaviour (Cowgill and Muscarella,
2003). Small GTP-binding proteins of the Ras superfamily,
including Rho, Rab, Raf, Rac and Rap, are involved in diverse
cellular functions such as cytokinesis, cell motility, cell adhesion
and cell proliferation (Etienne-Manneville and Hall, 2002). Signal
transduction is mediated through the activation of the p21ras as a
consequence of GTP binding to the protein and through the
activation of mitogen-activated protein kinases (MAPKs) belong-
ing to the serine/threonine protein kinase family (Kolch, 2002).
Before either ras and ras-related proteins can be biologically active,
they undergo isoprenylation at the COOH-terminal CAAX motif
(Liang et al, 2002). Recently, the 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitors have received great
attention for their cholesterol-independent (pleiotropic) effects,
such as the possible inhibition of small GTP-binding proteins Rho,
Ras and Rac isoprenylation (Liao, 2002). Moreover, preclinical
data seem to suggest an important role of statins as pharmaco-
logical tools for controlling abnormal cell growth, such as myocyte
or cancer cell proliferation (Kaushal et al, 2003); lovastatin and
other statins suppressed the proliferation of numerous cancer cell
lines, including human pancreas cancer cells, and exhibited a
trigger activity in tumour-specific apoptosis (Wong et al, 2002).
Holstein and Hohl (2001b) demonstrated a synergistic interaction
between paclitaxel or cytosine arabinoside (Holstein and Hohl,
2001a) and lovastatin on human cancer cell lines, whereas Feleszko
et al showed a potentiated antitumour activity of cisplatin
(Feleszko et al, 1998) and doxorubicin (Feleszko et al, 2000) in
murine tumour models when associated with lovastatin. Fluvas-
tatin, the first entirely synthetic hydrophylic HMG-CoA reductase
inhibitor, is presently used for the treatment of patients with
hypercholesterolaemia (Lawrence and Reckless, 2002). It has
similar efficacy and tolerability profiles than other HMG-CoA
reductase inhibitors, but, unlike them, it has not been associated
with rhabdomyolysis and myopathy (Scripture and Pieper, 2001).
Few reports have been focused on fluvastatin inhibition of cancer
cell proliferation (Seeger et al, 2003) and its possible mechanism of
action (Kusama et al, 2001, 2002). To our knowledge, no
combination studies have been performed with currently available
chemotherapeutic drugs in order to test a hypothetic synergism
with their anticancer activity and the molecular basis of the
eventual positive interaction. The cytosine arabinoside analogue
20,20-difluorodeoxycytidine (gemcitabine) has been proven to be
active in the treatment of pancreatic cancer (Abbruzzese, 2002a)
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swith significant clinical benefit, but still with marginal survival
advantage (El Rayes et al, 2003). Gemcitabine inhibits cell growth
by interfering with the synthesis of DNA (Barton-Burke, 1999), and
efforts are currently being made to increase the therapeutic
efficacy of the drug in clinical settings on various types of cancer
by combination with other agents, including cisplatin, oxaliplatin,
irinotecan, docetaxel, 5-fluorouracil, capecitabine or pemetrexed
(Heinemann, 2002; Jacobs, 2002). Moreover, numerous preclinical
experimental studies have been made to enhance the antitumour
effects of gemcitabine using novel therapeutic approaches such as
the proteasome inhibitor bortezomib (Kamat et al, 2004) and the
antiangiogenic drug SU5416 (Bocci et al, 2004).
Gemcitabine and fluvastatin do not have overlapping toxicities;
therefore, the association of these compounds might be an
attractive clinical alternative for the treatment of advanced
pancreatic tumours. The purposes of this study are to determine:
(1) the antiproliferative, proapoptotic effects of fluvastatin on k-
ras-mutated MIAPaCa-2 human pancreatic cancer cells and its
probable mechanism of action; (2) the synergistic enhancement of
cytotoxicity by the combination with gemcitabine; (3) the possible
underlying molecular basis of the synergism with pharmacological
tools such as PD98059, a MEK1/2 inhibitor that can block
activation of downstream ERK-1/2, and the expression of genes
such as the deoxycytidine kinase (dCK), a rate-limiting enzyme
required for the activation of gemcitabine, and the 50-nucleotidase
(50-NT), responsible for deactivation of gemcitabine; (4) the in vivo
effects of the fluvastatin/gemcitabine combination on MIAPaCa-2
xenografts in nude mice.
MATERIALS AND METHODS
Materials and animals
Antipain, leupeptin, aprotinin, sodium dodecyl sulphate (SDS) and
proteinase K were obtained from Roche Molecular Biochemicals
(Mannheim, Germany). DMEM medium, foetal bovine serum
(FBS), foetal calf serum (FCS), horse serum (HS), L-glutamine,
penicillin, streptomycin, agarose and 180bp DNA ladder were
from Gibco (Gaithersburg, MD, USA), swine serum was from Dako
(Milan, Italy) and acrylamide was purchased from Bio-Rad
(Melville, NY, USA). Diethylamine (DEA) and Nonidet P-40 were
obtained from ICN Biomedicals Inc. (Costa Mesa, CA, USA);
mouse IgG1 anti-p21ras monoclonal antibody was purchased from
Transduction Laboratories (Lexington, KY, USA), whereas anti-
p21rhoA and anti-p42MAPK/ERK2 rabbit polyclonal antibodies
were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Horseradish peroxidase-conjugated secondary antibodies and
reagents for chemiluminescence detection of proteins in immuno-
blots were purchased from Amersham Life Science (ECL Western
detection kit, Little Chalfont, UK). Universal Mount was from
Research Genetics Inc. (Huntsville, AL, USA). Quantitative real-
time polymerase chain reaction (PCR) reagents were purchased
from Applied Biosystems (Foster City, CA, USA). All other
chemicals not listed in this section were obtained from Sigma
Chemical Co. (St Louis, MO, USA). Fluvastatin (Novartis, Basel,
Switzerland) and gemcitabine (Ely Lilly and Company, Indiana-
polis, IN, USA) were dissolved in sterile distilled water, then
diluted in sterile culture medium immediately before their in vitro
use, or in sterile saline solution for in vivo use. Plastic for cell
culture was supplied by Costar (Cambridge, MA, USA). PD98059
was purchased from Calbiochem Biochemicals (Milano, Italy),
dissolved in DMSO and diluted in culture medium.
The CD nu/nu male mice, weighing 20–25g, were supplied by
Charles River (Milan, Italy) and were allowed unrestricted access
to food and tap water. Housing and all procedures involving
animals were performed according to the protocol approved
(approval number 11/04) by the ‘Comitato di Ateneo per la
sperimentazione animale’ (Academic Committee for the animal
experimentation) of the University of Pisa, in accordance with the
European Community Council Directive 86-609, recognised by the
Italian government, on animal welfare and the guidelines of the UK
Co-ordination Committee on Cancer Research (UKCCCR). Each
experiment employed the minimum number of mice needed to
obtain statistically meaningful results.
Cell culture conditions
The human pancreatic cancer cell line MIAPaCa-2 was obtained
from the American Type Culture Collection (ATCC, Manassas, VA,
USA). MIAPaCa-2 cells were maintained in DMEM medium,
supplemented with 10% FBS, 2.5% HS, penicillin (50IUml
 1),
streptomycin (50mgml
 1) and L-glutamine (2mM). The human
colon cancer cell line COLO320-DM, a cell line with wild-type
K-ras (Di Paolo et al, 2000), was from ATCC and maintained in
RPMI 1640 medium supplemented with 10% FBS, penicillin and
L-glutamine. Cells were routinely grown in 75cm
2 tissue culture
flasks and kept in a humidified atmosphere of 5% CO2 at 371C.
Cells were harvested with a solution of 0.25% trypsin–0.03%
EDTA when they were in log phase of growth, and maintained at
the above-described culture conditions for all experiments.
Polymerase chain reaction analysis of K-ras sequence in
the MIAPaCa-2 cell line
In order to demonstrate a possible mutation of K-ras sequence, the
mutational analysis of the codon 12 of the K-ras gene was
performed in MIAPaCa-2 cells by oligodeoxynucleotide hybridisa-
tion, as described previously (Marchetti et al, 1996). Briefly, as a
negative control the CLONE cell line (ATCC), derived from a
normal human corneal epithelium, was analysed, while as a
positive control a sample of human lung adenocarcinoma
with mutation at codon 12 (GGT-TGT, Gly-Cys) was used.
The primers used to amplify the K-ras gene around codon 12
were: 50-GGCCTGCTGAAAATGACTGA-30 and 50-TGATTCTGAAT
TAGCTGTAT-30. The amplified products of the PCR were
denatured, blotted onto nylon membranes and then hybridised
with
32P-labelled oligonucleotide probes designed to detect ras
mutations.
Cytotoxicity assay
In vitro chemosensitivity testing was performed on single-cell
suspensions of MIAPaCa-2 cells (2 10
4cellswell
 1) plated in six-
well sterile plastic plates and allowed to attach overnight. The
treatment protocol was designed so that each drug concentration
was represented by at least nine wells. Cells were treated with
gemcitabine (1–500nM) or PD98059 (1–100mM), or fluvastatin
(0.1–20mM) for 72h with or without mevalonic acid 100mM;i n
separate experiments, cells received drugs either simultaneously or
sequentially as described below. Furthermore, in order to test
fluvastatin antiproliferative activity on a wild-type k-ras cancer cell
line, 2 10
4 COLO320-DM cells per well were treated with
fluvastatin (0.1–100mM) for 72h. At the end of the experiment,
cells were photographed with a phase-contrast microscope Leitz
MD IL (Leica, Heerbrugg, Switzerland) and then washed with PBS,
harvested with trypsin/EDTA, and counted with a haemocyt-
ometer. The survival of treated cells was expressed as a percentage
of control (vehicle treated) cultures. The concentration of drugs
that reduced cell survival by 50% (IC50) as compared to controls
was calculated. Fluvastatin combined with gemcitabine was
explored with three different treatment schedules at a fixed molar
concentration ratio of 100:1 in MIAPaCa-2 cells, as follows: (A)
simultaneous exposure: fluvastatin (0.1–20mM) plus gemcitabine
(1–200nM) for 72h; (B) sequential exposure: fluvastatin (0.1–
20mM) alone for 24h, fluvastatin (0.1–20mM) plus gemcitabine
(1–200nM) for 24–72h and gemcitabine alone for 72–96h;
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s(C) reverse exposure: gemcitabine (1–200nM) alone for 24h,
gemcitabine (1–200nM) plus fluvastatin (0.1–20mM) for 24–72h
and fluvastatin (0.1–20mM) alone for 72–96h. Therefore, the total
exposure of each drug was 72h. After drug exposure, the media of
cell cultures were discarded and fresh medium was supplied to
cells. Furthermore, PD98059 (0.1–5mM) and gemcitabine (1–
50nM) were administered simultaneously for 72h to the pancreatic
cells at a fixed molar concentration ratio of 100:1.
Assessement of synergism or antagonism
To evaluate the level of interaction (synergistic, additive or
antagonist) between gemcitabine and fluvastatin or PD98059, the
method proposed by Chou et al (1993) was followed. Briefly,
synergism or antagonism for gemcitabine plus fluvastatin or
PD98059 is calculated on the basis of the multiple drug-effect
equation, and quantitated by the combination index (CI), where
CIo1, CI¼1 and CI41 indicate synergism, additive effect and
antagonism, respectively. Based on the classic isobologram, the CI
value is calculated as:
CI ¼½ ð DÞ1=ðDxÞ1 þ½ ð DÞ2=ðDxÞ2 
At the 75% inhibition level, (Dx)1 and (Dx)2 are the concentra-
tions of gemcitabine and fluvastatin or PD98059, respectively, that
induce a 75% inhibition of cell growth; (D)1 and (D)2 are the
concentrations of gemcitabine and fluvastatin or PD98059 in
combination that also inhibits cell growth by 75% (isoeffective as
compared with the single drugs alone). The dose-reduction index
(DRI) defines the degree of dose reduction that is possible in
combination for a given degree of effect as compared with the
concentration of each drug alone:
ðDRIÞ1 ¼ð DxÞ1=ðDÞ1 andðDRIÞ2 ¼ð DxÞ2=ðDÞ2
Quantitative, real-time PCR analysis of dCK and 50-NT
gene expression
To evaluate the expression of the dCK, a rate-limiting enzyme
required for the activation of the pyrimidine analogue gemcita-
bine, and of the cytosolic 50-NT, responsible for deactivation of
nucleotides and of the activated gemcitabine (Danesi et al, 2003),
MIAPaCa-2 cells were treated with fluvastatin (1 and 5mM)o r
vehicle alone for 72h. Quantitative real-time PCR analysis was
performed as described previously (Giovannetti et al, 2005).
Briefly, RNA (1mg) was reverse transcribed at 371C for 1h in a
100-ml reaction volume containing 0.8mM deoxynucleotide mix
(dNTPs), 200U of Moloney murine leukaemia virus reverse
transcriptase (MMLV-RT), 40U of RNase inhibitor and
0.05mgml
 1 random primers. The resulting cDNA was diluted
(2:3) and then amplified by QRT-PCR with the Applied
Biosystems 7900HT sequence detection system (Applied Biosys-
tems). Polymerase chain reaction thermal cycling conditions,
design and optimisation of primer concentrations were reported in
detail by Giovannetti et al (2005). Amplifications were normalised
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and the
quantitation of gene expression was performed using the DDCt
calculation, where Ct is the threshold cycle; the amount of target,
normalised to the endogenous control and relative to the calibrator
(untreated control cells), is given as 2 DDCt.
Assay of apoptosis
The internucleosomal DNA fragmentation was assayed as reported
(Danesi et al, 1995), with minor modifications. Briefly, MIAPaCa-2
cells were plated in 100mM sterile dishes for cell culture and
treated for 72h with gemcitabine 20–200nM, fluvastatin 0.5–20mM
alone or in combination with mevalonic acid 100mM, or their
simultaneous combination at a fixed concentration ratio of 1:100
of gemcitabine/fluvastatin. Furthermore, in order to test fluvasta-
tin proapoptotic activity on a wild-type k-ras cancer cell line,
COLO320-DM cells were treated with fluvastatin (3–50mM) for
72h. At the end of incubation, 2 10
6 cells per treatment were
washed with PBS, harvested with trypsin-EDTA and pelleted by
centrifugation. Cells were lysed in Tris-EDTA buffer for 90min at
41C. Cellular lysates were centrifuged at 15000r.p.m. for 1h at 41C,
and clear supernatants containing fragmented chromatin were
incubated at 421C for 30min in the presence of proteinase K
(200mgml
 1), and extracted by treatment with phenol:chlorofor-
m:isoamyl alcohol (25:24:1), vigorously shaken for 30s and
centrifuged at 15000r.p.m. for 10min. Supernatants were collected
and mixed with 100ml of NaCl 5 M, 1ml of cold 100% ethanol and
1ml of glycogen. The suspension were kept at  201C overnight to
precipitate DNA fragments, then centrifuged at 15000r.p.m. for
30min. Pellets were washed with 70% ethanol and dried under air
flow. Samples were resuspended in Tris-EDTA buffer containing
1mgml
 1 boiled bovine pancreatic RNAse A, incubated for 1h at
401C, and finally mixed with DNA sample buffer. Electrophoresis
was performed in 1% agarose gel in Tris-EDTA-acetate buffer, and
bands were visualised by ethidium bromide staining and UV
transillumination. A 123-bp DNA ladder was run as a standard. Gel
was photographed with a Polaroid MP4 Land camera (Polaroid,
Cambridge, MA, USA) and pictures were digitised for the analysis
of DNA fragmentation as described in the section ‘Analysis of
data’.
Cell cycle analysis
Cells were plated in 100mm sterile dishes for cell culture
and treated for 72h with gemcitabine 1–50nM or fluvastatin
0.1–10mM. At the end of the experiment, cells were washed with
PBS and harvested with EDTA (0.5mM), centrifuged, resuspended
in PBS and counted. Flow cytometry analysis of DNA content was
performed in 75% ethanol-fixed cells, washed twice in PBS/0.1%
NaN3/1% FCS and filtrated through a 35mm nylon gauze filter;
1 10
6 cellsml
 1 were stained for 30min at 41C in the dark with
50mgml
 1 propidium iodide solution containing 100Uml
 1
RNAse and 0.1% Nonidet P-40. Flow cytometry analysis was
performed on FACSort flow cytometry apparatus (Becton Dick-
inson, San Jose, CA, USA), equipped with a laser for excitation at
488nM. CellQuest version 3.1 and ModFit LT2 version 2.0 (Verity
Software House Inc., ME, USA) softwares were used for analysis of
cell cycle distribution and quantitation of S-phase fraction on at
least 20000 nuclei. Clumped cells, doublets and higher aggregates
were gated out using electronic pulse-processing (peak vs
integrated DNA fluorescence signals) and measurement accuracy
was evaluated considering the coefficient of variation (CV) of the
G0/G1 peaks.
Immunoblot analysis of p21ras, p21rhoA and
p42MAPK/ERK2
Total cellular extracts were analysed for p21ras and p21rhoA by
immunoblotting. Briefly, cells exposed to fluvastatin (2–10mM)o r
gemcitabine (1–50nM) for 72h alone or in combination with
mevalonic acid 100mM and untreated controls were harvested with
EDTA 0.5mM, washed with PBS and centrifuged. The cells were
solubilised at 41C in lysis buffer (Tris-base 50mM, pH 7.6, 2mM
EDTA, 100mM NaCl, 1% Nonidet P-40, 1mM PMSF, 2mgml
 1
aprotinin, 2mgml
 1 pepstatin, 2mgml
 1 antipain) for 60min. Cell
lysate was centrifuged at 15000r.p.m. for 20min at 41C and
aliquots of supernatants were used to measure protein concentra-
tion. Samples were boiled for 3min in SDS-sample buffer (50mM
Tris-base, pH 6.8, 2% SDS, 100mM dithiothreitol, 10% glycerol and
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s0.025% b-mercaptoethanol) and separated on 15% SDS–poly-
acrylamide gel electrophoresis (SDS–PAGE). Proteins were then
transferred onto Immobilon-P membrane (Millipore, Bedford, MA,
USA) and blots were probed with an anti-p21ras (1:500) or anti-
p21rhoA antibody (1:1000), and detected with the use of horse-
radish peroxidase-conjugated secondary antibody (dilution,
1:10000). The membranes were then exposed to Kodak X-Omat
AR film, and film densities were quantified as described in
‘Analysis of data’. To evaluate the effect of fluvastatin and
gemcitabine on p42MAPK/ERK2 phosphorylation, MIAPaCa-2
cells were treated with fluvastatin (2–10mM) or gemcitabine
(1–50nM) for 72h alone or in combination with mevalonic acid
100mM. Cells were solubilised in lysis buffer with the protein
phosphatase inhibitors sodium metavanadate and sodium fluoride
(200mM each) for 45min at 41C, and then centrifuged at 41C for
20min at 15000r.p.m. The supernatant was boiled for 3min in
SDS-sample buffer and separated on 11% SDS–PAGE. Proteins
were transferred onto Immobilon-P membrane and probed with
anti-p42MAPK/ERK2 antibody (1:1000), and detected as de-
scribed above.
Immunocytochemistry
Cells were seeded onto chamberslides (Nalge Nunc, Naperville, IL,
USA) at a density of 10
4 per 150ml; after treatment with fluvastatin
at 2mM for 48h or vehicle, cells were washed in PBS and fixed with
1% neutral buffered formalin (10min) at 41C. The specimens were
then permeabilised with a 10-min exposure to a solution of 0.2%
Triton X-100–PBS. The samples were subsequently treated with a
solution of 3% H2O2 for 5min to quench endogenous peroxidase
activity, and nonspecific reactivity was blocked with 5% swine
serum for 20min at 371C. The samples were then incubated
overnight at 41C in a humidified chamber with the mouse anti-
human-p21rhoA or anti-human-Ha-p21ras antibody (1:20–1:50
in 0.1% BSA-PBS). The detection protocol was carried out using
biotinylated secondary antibodies and a streptavidin–peroxidase
complex (LSAB kit, Dako). The reaction was developed by
incubating samples in the substrate–chromogen solution
(1mgml
 1 3,30-diaminobenzidine tetrahydrochloride containing
0.02% H2O2) for 5min in the dark. Finally, the slides were
mounted with Universal Mount and observed with a DMRB Leica
microscope equipped with a  100 oil immersion lens. Each
treatment was performed in three wells and observations were
made from 10 fields from each well. Negative controls were
obtained by substituting the primary antibodies with a non-
immune mouse serum or with 1 PBSþ0.1% BSA, or by using
primary antibodies not raised against p21rhoA or Ha-p21ras (e.g.,
anti-human TGFa immunoglobulins; Oncogene Science, Union-
dale, USA). Endogenous peroxidase and avidin-binding activity
were tested by incubating the slides with 3,30-diaminobenzidine
tetrahydrochloride alone or with streptavidin–HRP complex
alone, followed by 3,30-diaminobenzidine tetrahydrochloride,
respectively.
In vivo studies
MIA PaCa-2 cell viability was assessed by trypan blue dye
exclusion, and, on day 0, 1.3 10
675% cells per mouse were
inoculated subcutaneously between the scapulae in 0.2ml per
mouse of culture medium without FBS using an insulin syringe
with a 0.5 16mm needle. Animal weights were monitored and
the appearance of a subcutaneous tumour that was measured every
2 days in two perpendicular directions using calipers. Tumour
volume (mm
3) was defined as follows: ((w1 w2 w2) (p/6)),
where w1 and w2 were the largest and the smallest tumour
diameters (mm), respectively. The mice were randomised into
groups of five. In order to treat an established tumour (B35mm
3),
at day 15 from the cell inoculum, fluvastatin, gemcitabine or their
simultaneous combination was administered intraperitoneally as
follows: (1) fluvastatin every 2 days at a dose of 30mgkg
 1 for 14
days (cumulative dose of 210mgkg
 1 per mouse equivalent to the
study by Ferrara et al, 2003); (2) gemcitabine 120mgkg
 1 four
times at 3-day intervals as described previously (Braakhuis et al,
1995); (3) combination treatment of fluvastatin and gemcitabine.
The control group was injected i.p. with vehicle alone (saline
solution). The experimental period ended 11 days after the last
injection of fluvastatin and mice were killed by an anaesthetic
overdose.
Analysis of data
Film densities of protein immunoblots and apoptosis assays were
quantified through video imaging densitometry with the KS300
version 1.2. software (Kontron Elektronic, Eching, Germany), and
expressed as arbitrary units of mean gray values (optical density),
in the range of 0–255, where 0 was black and 255 was white (Di
Paolo et al, 2000). Results were expressed as the mean7s.e. of the
optical density ratio between the gray values of isoprenylated and
nonisoprenylated proteins for p21rhoA and p21ras, and between
the nonphosphorylated and phosphorylated immunoblot bands
for p42ERK2/MAPK. The degree of apoptosis was assessed by
single-band densitometric analysis of DNA fragments in the range
of 180–900bp. The analysis by ANOVA, followed by the Student–
Newman–Keuls test, was used to assess the statistical differences
of data obtained in control and treated cells with respect to
immunoblotting, cytotoxicity, real-time RT–PCR results and in
vivo studies. P-values lower than 0.05 were considered significant.
RESULTS
Presence of K-ras gene mutation in the MIAPaCa-2 cell line
The analysis of DNA extracted from MIAPaCa-2 cells demon-
strated a homozygous GGT-TGT mutation at codon 12 of K-ras
gene, while one allele of the lung tumour sample was mutated; cells
from normal cornea showed two normal alleles (Figure 1).
Cytotoxicity of gemcitabine and fluvastatin
Gemcitabine and fluvastatin inhibited cell growth of MIAPaCa-2
cell line in a concentration-dependent manner (Figure 2A), and the
IC50 values were 19.770.4nM and 1.0770.27mM, respectively. The
cytotoxic activity of gemcitabine 1–500nm was not modified
by mevalonic acid 100mM (IC50¼13.871.2nM; Figure 2A), while
the antiproliferative effect of fluvastatin 0.1–20mM was greatly
reduced and reversed by adding mevalonic acid 100mM in the
medium (Figure 2A), as demonstrated by the IC50 value
(IC50¼18.8371.2mM) being significantly different from that
observed in the absence of mevalonic acid (Po0.05). Moreover,
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Figure 1 Dot-blot hybridisation analysis of point mutations (GGT-
TGT) at codon 12 of the K-ras oncogene in MIAPaCa-2 and lung tumour;
normal cornea (clone cell line) shows wild-type K-ras.
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sthe PD98059 72-h treatment showed an antiproliferative effect on
serum-stimulated MIAPaCa-2 cells, as demonstrated by the
experimental IC50 of 6.1370.8mM. In order to further test the
antiproliferative activity of fluvastatin on a wild-type k-ras cancer
cell line, COLO320-DM cells were chosen. Fluvastatin inhibited
COLO320-DM cell proliferation in a dose-dependent manner
(Figure 2B), and the calculated IC50 value was 4.9070.68mM. The
cytotoxic activity of fluvastatin on COLO320-DM cell growth was
significantly reduced by a concentration of 100mM mevalonic acid
(Figure 2B).
From a morphological point of view, MIAPaCa-2 cells treated
with vehicle alone grew in large colonies as confluent monolayers
with an epithelial-like shape (Figure 3). Most cells treated with
fluvastatin 2mM for 72h became rounded and the proportion of
floating cells increased in a concentration-dependent manner
(Figure 3); also, gemcitabine 20nM determined marked aspecific
degenerative alterations of cell shape after 72h (Figure 3).
Simultaneous and sequential exposure to fluvastatin and gemci-
tabine showed synergism at effect levels exceeding 60% inhibition
(Table 1). Synergism corresponding to CIo1 always yielded a
favourable DRI (41) for both drugs (Tables 1 and 2). The DRI
values at IC50,I C 75 and IC95 are reported in Table 2. Figure 4A
shows a representative isobologram of MIAPaCa-2 cells exposed to
gemcitabine and fluvastatin for 72h with different schedules of
treatment. Furthermore, the simultaneous treatments of gemcita-
bine and PD98059 for 72h were synergistically active on pancreatic
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Figure 2 (A) Effect of fluvastatin, gemcitabine and their combination
with mevalonic acid 100mM on k-ras-mutated MIAPaCa-2 cell proliferation;
(B) effect of fluvastatin and its combination with mevalonic acid 100mM on
wild-type k-ras COLO320-DM cell proliferation. Symbols and bars, mean
values7s.e., respectively; *Po0.05 vs fluvastatin only.
Figure 3 Microscopic pictures of control MIAPaCa-2 cells (A) and cells
treated with fluvastatin 2mM (B) or gemcitabine 20nM (C). Original
magnification  100.
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Figure 4B. The position of the data points on the left of the line
connecting the IC75 values of gemcitabine and fluvastatin or
PD98059 indicates synergism for all schedules (Figure 4A and B).
dCK and 50-NT gene expression in fluvastatin-treated
cancer cells
Fluvastatin, at its 1 and 5mM concentrations, significantly
increased dCK expression (e.g. at 1mM, 271.6 vs 100% of controls)
in the MIAPaca-2 cell line, whereas, at the same concentrations,
there was a significant decrease of 50-NT expression (e.g. at 1mM,
71.1 vs 100%; Figure 5). Thus, both the simultaneous significant
increase in the expression of the activating enzyme (dCK) and the
decrease of the deactivating one (50-NT) suggested a possible role
of fluvastatin in the activating metabolism of gemcitabine in
pancreatic cancer cells.
Induction of apoptosis by gemcitabine, fluvastatin and
their combination
The extent of DNA fragmentation was dependent on the
concentration of both drugs (Figure 6A). In particular, the
production of chromatin fragments was clearly detectable after
72h in a dose-dependent manner for fluvastatin and gemcitabine
(Figure 6A). The use of mevalonic acid 100mM determined a
complete reversion of the apoptosis induced by fluvastatin, but not
by gemcitabine, on MIAPaCa-2 cells (data not shown). Image
analysis of DNA fragmentation confirmed that the increase in drug
concentrations was associated with enhanced optical density of
DNA bands corresponding to shorter fragments (180–900bp;
Figure 6A). A plateau was reached at the highest concentration of
fluvastatin; finally, the simultaneous treatment of MIAPaCa-2 cells
with fluvastatin/gemcitabine at the 100:1 concentration ratio was
associated with a marked increase in apoptosis (Figure 6A). The
concentration-dependent proapoptotic effects of 72h fluvastatin
treatment were confirmed also in the wild-type k-ras COLO320-
DM cancer cell line (Figure 6B).
Cell-cycle-specific effects of gemcitabine and fluvastatin
The DNA histograms obtained from MIAPaCa-2 cells treated with
fluvastatin or gemcitabine showed a dose-dependent drug effect on
the cell cycle distribution (Figure 7). When the treatment with
fluvastatin was prolonged up to 72h, the G2/M peak declined
Table 1 CI values for the three drug combinations at 75, 90 and 95%
levels of inhibition of MIA PaCa-2 cell growth
CI values (mean7s.e.)
Drug combination 75% 90% 95%
Fluvastatin+gemcitabine 0.5470.03 0.2670.01 0.1670.01
Fluvastatin-gemcitabine 0.6670.04 0.3370.02 0.2270.01
Gemcitabine-fluvastatin 0.6270.01 0.2970.004 0.1870.002
Arrows indicate the sequence of treatment.
Table 2 DRI values for the three combinations at 75, 90 and 95% levels of inhibition of MIA PaCa-2 cell growth
DRI values (mean7s.e.)
75% 90% 95%
Drug combination Fluvastatin Gemcitabine Fluvastatin Gemcitabine Fluvastatin Gemcitabine
Fluvastatin+gemcitabine 7.0570.37 2.5370.13 4.8170.24 19.2970.97 7.4570.36 38.2571.84
Fluvastatin-gemcitabine 5.7870.36 2.0870.13 3.4770.22 14.9870.88 5.5870.31 28.6371.60
Gemcitabine-fluvastatin 6.0970.11 2.1970.04 4.2670.07 17.0770.27 6.6770.13 34.4170.51
Arrows indicate the sequence of treatment.
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Figure 4 Isobologram analysis of MIAPaCa-2 cell growth inhibition by
(A) gemcitabine and fluvastatin simultaneously and sequentially, and (B)
gemcitabine and PD098059 simultaneously. The IC75 values of each drug
are plotted on the axes; the solid line represents the addictive effect, while
the points representing the concentrations of gemcitabine and fluvastatin or
PD098059 resulting in 75% growth inhibition of the combination are
reported on the left of the connecting line, indicating synergism.
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sconcomitantly to the appearance of a dose-dependent subdiploid
peak (sub G1), typical of apoptotic cells, starting from a
concentration of 2mM (Figure 7). Gemcitabine induced an S-phase
accumulation of cells after 72h of treatment, with the simultaneous
appearance of the subdiploid peak, starting at 20nM (Figure 7).
Apoptosis was quantified and measured as the percentage of
subdiploid cells on the DNA histogram. Both fluvastatin and
gemcitabine caused a significant dose-dependent increase in
apoptosis (Po0.05; Figure 7), thus confirming the data obtained
from agarose gel electrophoresis.
Inhibition of p21rhoA and p21ras prenylation and
phosphorylation of p42MAPK/ERK2 by fluvastatin
Immunoblots of MIAPaCa-2 cells demonstrated that fluvastatin
inhibited the post-translational processing of immature p21rhoA,
causing the appearance of nongeranyl-geranylated p21rhoA
proportional to the drug concentrations (Figure 8A). The image
analysis of protein bands, computed as the ratio between the mean
gray values of the prenylated vs nonprenylated band on Western
blots of p21rhoA, confirmed that fluvastatin significantly increased
the amount of immature, nonisoprenylated protein in a concen-
tration-dependent manner (Figure 8A). The cells treated simulta-
neously with fluvastatin and 100mM mevalonic acid presented only
the band corresponding to the geranyl-geranylated protein. In
contrast, gemcitabine, with or without mevalonic acid 100mM, did
not affect the geranyl-geranylation of p21rhoA on immunoblots
(Figure 8A). In addition to this, fluvastatin determined the same
concentration-dependent effects on p21ras, as shown by the
appearance of a band shift representing the nonfarnesylated
peptide (Figure 8B), as confirmed by image analysis (Figure 8B).
Compared to controls, gemcitabine did not affect protein mobility
in immunoblots due to inhibition of protein prenylation; on the
contrary, the simultaneous treatment of fluvastatin with 100mM
mevalonic acid markedly reduced the nonfarnesylated bands
(Figure 8B). Furthermore, fluvastatin reduced the amount of the
active, phosphorylated form of p42MAPK/ERK2 (Figure 8C), and
the optical density ratio of phosphorylated/nonphosphorylated
p42MAPK/ERK2 protein bands of treated cells appeared signifi-
cantly decreased (Po0.05; Figure 8C). Mevalonic acid contrasted
the concentration-dependent effects of fluvastatin, whereas gemci-
tabine did not affect the ras prenylation (Figure 8C).
Immunocytochemical localisation of p21rhoA and p21ras
proteins
Untreated MIAPaCa-2 cells showed a higher degree of immunor-
eactivity compared to fluvastatin-treated cells. A specific p21rhoA
positivity was localised along the plasma membrane and the
peripheral cytoplasmic boundaries of control cells (Figure 9A). In
contrast, fluvastatin-treated cells displayed only a weak positivity
homogeneously localised within the cytoplasm without specific
immunostaining at the level of cell membranes (Figure 9B).
Concerning anti-p21ras, the highest immunoreactivity was ob-
served in control cells along the plasma membranes, with a faint
immunostaining in their cytoplasm (Figure 9C). On the contrary,
most of the fluvastatin-treated cells displayed a weak anti-p21ras
immunoreaction localised mainly in the cytoplasm (Figure 9D); no
specific localisation of the p21ras peptide was observed at the level
of the plasma membranes or nuclei.
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Figure 6 (A) Gel electrophoresis of DNA extracted from fluvastatin-
and gemcitabine-treated k-ras-mutated MIAPaCa-2 cells (upper). Image
analysis of apoptotic DNA from cells exposed to fluvastatin, gemcitabine
and their combination (lower); (B) gel electrophoresis of DNA extracted
from 72h fluvastatin-treated wild-type k-ras COLO320-DM cells. C,
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sEnhanced inhibition of tumour growth in vivo by the
simultaneous combination of fluvastatin and gemcitabine
MIAPaCa-2 cells injected s.c. in CD nu/nu mice grew quite rapidly
and tumour masses became detectable 9 days after xenotrans-
plantation. Tumours in control animals showed a progressive
enlargement in their dimensions, and a mean volume of
B550mm
3 was reached at the end of the experimental period
(Figure 10A). Both fluvastatin and gemcitabine were able to inhibit
tumour growth, although to different extents, and their therapeutic
effect was significant starting on the 19th day after implant as
compared to controls (Figure 10A). In the group of animals
receiving the combined treatment with fluvastatin and gemcita-
bine, the reduction in tumour growth was significant already on
day 19 with respect to controls (Figure 10A). The tumour growth
curve of fluvastatinþgemcitabine showed a significant decrease
during the 14-day schedule, divergent from that of controls, as well
as from fluvastatin- and gemcitabine-treated animals, and at days
22 and 27 the tumour volume was significantly different from that
of controls and of animals given fluvastatin and gemcitabine alone,
respectively (Figure 10A). It is noteworthy that the combination of
fluvastatin and gemcitabine resulted in an almost complete
regression of tumour volumes (Figure 10A). Interestingly, all
the drug schedules showed tumour relapses in all the treated
groups at the end of the experiments, but with a significant delay
in the case of the combination treatment. The toxicity profile was
favourable and acceptable for both single and combination
treatment, with no loss of weight throughout the course of the
experiment (Figure 10B).
DISCUSSION
The present study shows that fluvastatin inhibits proliferation,
induces apoptosis in both human pancreatic cancer MIAPaCa-2
cells harbouring a p21ras mutation at codon 12 and in wild-type k-
ras COLO320-DM cancer cells (although in different extent), and
synergistically potentiates the cytotoxic effect of gemcitabine on
these cancer cells. The pharmacologic effects of fluvastatin are
prevented by treatment with mevalonic acid, suggesting that the
demonstrated inhibition of geranyl-geranylation and farnesylation
of cellular proteins, including p21rhoA and p21ras, plays a major
role in its anticancer effect. Fluvastatin treatment also indirectly
inhibits the phosphorylation of p42ERK2/MAPK, the cellular
effector of ras and other signal transduction peptides. Indeed, a
similar synergistic effect against cancer cell proliferation is
obtained combining gemcitabine and PD98059, a MEK1/2
inhibitor that can block activation of downstream ERK-1/2
(Boucher et al, 2000), confirming the importance of this signal
pathway in the observed experimental data. Moreover, fluvastatin
treatments simultaneously increase the expression of the dCK, the
enzyme required for the activation of gemcitabine, and reduce the
50-NT, responsible for deactivation of gemcitabine, suggesting a
possible additional role of these enzymes in the enhanced cytotoxic
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Figure 7 In vitro effect of fluvastatin and gemcitabine on cell cycle distribution of MIAPaCa-2 cells. Percent values of cells in different phases of the cell
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sactivity of gemcitabine in the combined treatment. Above all, the
described in vitro effects were confirmed in vivo, with a significant
enhancement of antitumour activity of the simultaneous admin-
istration of fluvastatin and gemcitabine.
Most studies of single-agent chemotherapy in patients with
advanced adenocarcinoma of the pancreas showed low response
rate and little impact on patient survival (Abbruzzese, 2002b). Ras
oncogene is very frequently mutated in human pancreatic cancer,
and its overexpression may be related to the neovascular and
metastatic process (Rak and Kerbel, 2001). Therefore, the
identification of new compounds able to affect ras and ras-related
functions, in association with gemcitabine, one of the most active
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Figure 8 (A) Immunoblotting (upper) and image analysis (lower) of p21rhoA from total cellular lysates of MIAPaCa-2 cells treated with fluvastatin and
gemcitabine. Columns and bars, mean values7s.e., respectively. MVA, mevalonic acid, G, geranyl-geranylated, N-G, nongeranyl-geranylated p21rhoA;
*Po0.05 vs controls. (B) Immunoblotting (upper) and image analysis (lower) of p21ras from total cellular lysates of MIAPaCa-2 cells treated with fluvastatin
and gemcitabine. Columns and bars, mean values7s.e., respectively. MVA, mevalonic acid, F, farnesylated, N-F, nonfarnesylated p21ras;* Po0.05 vs controls.
(C) Immunoblotting (upper) and image analysis (lower) of p42MAPK/ERK2 in MIAPaCa-2 cells treated with fluvastatin and gemcitabine. Columns and bars,
mean values7s.e., respectively. MVA, mevalonic acid, P, phosphorylated, N-P, nonphosphorylated p42MAPK/ERK2; *Po0.05 vs controls.
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schemotherapeutic drugs used in pancreas neoplasm, may repre-
sent a rational approach to the therapy of advanced pancreatic
cancer. Two of these agents, R-115777 and SCH-66336, are orally
active heterocyclic compounds and already in phase II/III studies
in patients (Dempke, 2003) with advanced pancreatic cancers to
determine the extent of their clinical activity. Indeed, durable
objective partial responses were noted in several patients
(Dempke, 2003). Fluvastatin in our experiments increases the
nonisoprenylated form of cellular proteins. Although farnesyl
protein transferase inhibitors are currently being evaluated in
phase II and III clinical trials (Zhu et al, 2003) and they were found
to be well tolerated (Dempke, 2003), there are still no data on their
long-term safety. On the other hand, statins have been in clinical
use for more than 15 years with a well-known, yet favourable,
toxicity profile, even if used for long periods. Fluvastatin has the
same toxicity profile as other HMG-CoA reductase inhibitors,
while it has not been associated with rhabdomyolysis and
myopathy (Scripture and Pieper, 2001). Furthermore, fluvastatin
has been safely administered at high doses in paediatric patients
with cancer (Lopez-Aguilar et al, 1999). Indeed, micromolar
concentrations of gemcitabine and fluvastatin have been reached
in human plasma in pharmacokinetic studies (Kroep et al, 1999;
Kantola et al, 2000), and these plasma levels are in the range of the
antiproliferative activity found in the present study. Moreover, the
administered fluvastatin dose in our in vivo experiment was based
on the study by Ferrara et al (2003), who showed, for the same
total dose given in 14 days, serum concentrations of fluvastatin in
mice higher than 1.2mgml
 1, representing drug levels of B2 times
the mean drug concentration in human plasma after a 40mg oral
dose and confirming the potential translation to the clinic of our
data.
The chemotherapeutic activity of gemcitabine is well known
(Bergman et al, 1996), and has been confirmed by MIA PaCa2 cells
used in this study, whereas the antiproliferative activity of
fluvastatin has been previously described only in breast cancer
cells (Mueck et al, 2003). Treatment with fluvastatin is associated
with tumour cell rounding, followed by cell detachment and
apoptosis. This morphological change has also been previously
described for the HMGCoA reductase inhibitor lovastatin in vitro
on mesangial cells (Ghosh et al, 1997) and attributed to the
inhibition of isoprenylation of small GTP-binding proteins that
regulates the formation of actin stress fibres and focal adhesion
plaques. In particular, in this study, fluvastatin inhibited the
Figure 9 Immunohistochemical localisation (dark staining) of p21rhoA in MIAPaCa-2 cells control (A) and treated with fluvastatin (B), and p21ras in
control cells (C) and treated with fluvastatin (D). Original magnification  200.
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Figure 10 (A) Chemotherapeutic effect of gemcitabine 120mgkg
 1 i.p.
four times at 3-day intervals and fluvastatin 30mgkg
 1 i.p. every 2 days
alone or in combination on MIAPaCa-2 tumours xenotransplanted in CD
nu/nu mice. *Po0.05 with respect to controls; **Po0.05 vs gemcitabine
and fluvastatin alone. Symbols and bars, mean7s.e. (B) Body weight of
MIAPaCa-2 tumour-bearing control mice and mice treated with gemcita-
bine and fluvastatin alone or in combination. No changes or decline in body
weight were noted. Symbols and bars, mean7s.e.
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sgeranyl-geranylation of p21rhoA, a protein involved in cytoskeletal
functions (Evers et al, 2000). Indeed, pancreatic cancer cells
treated with fluvastatin accumulate p21rhoA in the cytoplasm, as
shown by immunocytochemistry, because of the impairment of
post-translational processing and lack of membrane association of
the peptide.
To our knowledge, the data of the present study are the first
findings to demonstrate that fluvastatin has an antiproliferative/
proapoptotic effect on human pancreatic cancer cells. Fluvastatin
may induce cells to become more susceptible to apoptosis by
inhibiting the isoprenylation process, as demonstrated by the use
of mevalonic acid as a pharmacological tool to reverse its
antiproliferative and proapoptotic effects. In the combination
treatment, fluvastatin increased apoptosis in a synergistic manner.
By using the median-effect principle and the CI-isobologram
technique, a synergism has been demonstrated between fluvastatin
and gemcitabine in vitro, regardless of the schedule of adminis-
tration, thus allowing for a dose reduction in order to obtain the
same effect, with the consequence of lowering the toxicities of each
drug in combination. Moreover, the in vivo simultaneous
combination greatly inhibits human pancreatic tumours without
any remarkable side effect on mice. At the present time, no
association studies involving fluvastatin have been published yet;
however, it has been previously shown that lovastatin enhanced
the apoptosis induced by chemotherapeutic drugs, including 5-FU
and cisplatin, in colon cancer cell lines (Agarwal et al, 1999).
Furthermore, Holstein and Hohl (2001b) demonstrated synergism
between paclitaxel and lovastatin on human cancer cell lines,
whereas Feleszko et al (2002) showed an in vivo enhanced
antitumour activity of doxorubicin in murine tumour models
when associated with lovastatin.
In an effort to better explain the molecular basis of the
demonstrated synergistic effects between gemcitabine and fluvas-
tatin, the signal transduction pathway of the isoprenylated proteins
and the activating metabolism of gemcitabine were further studied.
The signal transduction to ras effectors was interrupted, as
demonstrated by the lack of activation in fluvastatin-treated cells
of p42MAPK/ERK2, a cytoplasmic serine/threonine proteine
kinase, responsible for the transduction of mitogenic signals
(Kolch, 2002). Indeed, the substitution of fluvastatin with the
MAPK/ERK kinase inhibitor PD098059 in combination with
gemcitabine produced similar synergistic results as the association
of fluvastatin and gemcitabine. These data could suggest that
MAPK activity suppression due to fluvastatin (through the
isoprenylation inhibition) or PD098059 is a key step to enhance
the cancer cell kill of gemcitabine, as also previously suggested
(Nelson and Fry, 2001).
Moreover, in our experimental setting, the greater effect of the
fluvastatin/gemcitabine combination could also be dependent on a
higher concentration and prolonged half-life of the active mono-,
di- and triphosphate metabolites of gemcitabine inside the
pancreatic tumour cells due to the fluvastatin induction of the
expression of dCK, which activates the drug by phosphorylation,
and the reduction of 50-NT, which removes the phosphate group
from cytotoxic metabolites (Danesi et al, 2003).
In conclusion, the results of the present study demonstrate
that the combination of gemcitabine and fluvastatin is an
effective cytotoxic, proapoptotic treatment in vitro and in vivo
against MIAPaCa-2 cells harbouring a mutated p21ras by a
mechanism of action mediated, at least in part, by the inhibition
of p21ras and rhoA prenylation. As stated recently by Wong
et al (2002), ‘understanding the molecular mechanism of
statin’s anti-cancer action remains outstanding’ for the clinical
management of patients and in this view, our data could contribute
to a better understanding of the fluvastatin cytotoxic mechanism
of action and to conceive new synergistic combinations in
order to maximise the efficacy and minimise the drug-related
toxicities in vivo, especially in the field of metastatic pancreatic
cancer, where few effective therapeutic choices are presently
available.
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